利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.017 秒)

    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
    1.
    发明授权
    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules 有权
    与人类白细胞抗原（HLA）II类分子有明显结合的肿瘤相关肽

    公开(公告)号：US07833969B2

    公开(公告)日：2010-11-16

    申请号：US11942598

    申请日：2007-11-19

    申请人： Jörn Dengjel

    发明人： Jörn Dengjel

    IPC分类号： A61K38/10

    CPC分类号： C07K14/4748 ,  A61K38/00 ,  C07K14/7051

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.

    摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的49种来自人类肿瘤细胞系HLA II类分子的新肽序列。

    Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
    2.
    发明授权
    Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes 失效
    来自人肿瘤抗原的免疫原性T辅助表位和使用所述表位的免疫治疗方法

    公开(公告)号：US08067529B2

    公开(公告)日：2011-11-29

    申请号：US11664627

    申请日：2005-09-09

    申请人： Hans-Georg Rammensee ,  Toni Weinschenk ,  Jörn Dengjel

    发明人： Hans-Georg Rammensee ,  Toni Weinschenk ,  Jörn Dengjel

    IPC分类号： C07H21/04 ,  C07K5/00 ,  C12N15/00

    CPC分类号： C07K14/4748

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.

    摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症，特别是肾癌的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的338种来自人类肿瘤细胞系的HLA II类分子的新型肽序列。

    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
    3.
    发明授权
    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules 有权
    与人类白细胞抗原（HLA）II类分子有明显结合的肿瘤相关肽

    公开(公告)号：US07833970B2

    公开(公告)日：2010-11-16

    申请号：US11942620

    申请日：2007-11-19

    申请人： Jörn Dengjel

    发明人： Jörn Dengjel

    IPC分类号： A61K38/10

    CPC分类号： C07K14/4748 ,  A61K38/00 ,  C07K14/7051

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.

    摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的49种来自人类肿瘤细胞系HLA II类分子的新肽序列。

    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
    5.
    发明授权
    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules 有权
    与人类白细胞抗原（HLA）II类分子有明显结合的肿瘤相关肽

    公开(公告)号：US08258260B2

    公开(公告)日：2012-09-04

    申请号：US11942561

    申请日：2007-11-19

    申请人： Jörn Dengjel

    发明人： Jörn Dengjel

    IPC分类号： A61K35/14

    CPC分类号： C07K14/4748 ,  A61K31/7088 ,  A61K39/00

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.

    摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的49种来自人类肿瘤细胞系HLA II类分子的新肽序列。

    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
    6.
    发明授权
    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules 有权

    公开(公告)号：US08211999B2

    公开(公告)日：2012-07-03

    申请号：US11942588

    申请日：2007-11-19

    申请人： Jörn Dengjel

    发明人： Jörn Dengjel

    IPC分类号： A61K39/00

    CPC分类号： C07K14/4748 ,  A61K38/00 ,  A61K39/00

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.

    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
    7.
    发明授权
    Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules 有权

    公开(公告)号：US08212000B2

    公开(公告)日：2012-07-03

    申请号：US11942607

    申请日：2007-11-19

    申请人： Jörn Dengjel

    发明人： Jörn Dengjel

    IPC分类号： A61K39/00

    CPC分类号： A61K39/0011 ,  A61K38/00

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.

    Tumor-associated peptides binding promiscuosly to human leukocyte antigen (HLA) class II molecules
    8.
    发明授权
    Tumor-associated peptides binding promiscuosly to human leukocyte antigen (HLA) class II molecules 有权
    肿瘤相关肽预先结合人白细胞抗原（HLA）II类分子

    公开(公告)号：US07807642B2

    公开(公告)日：2010-10-05

    申请号：US11942573

    申请日：2007-11-19

    申请人： Jörn Dengjel

    发明人： Jörn Dengjel

    IPC分类号： A61K38/00

    CPC分类号： C07K14/4748 ,  A61K38/00 ,  C07K14/7051

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.

    摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的49种来自人类肿瘤细胞系HLA II类分子的新肽序列。